InSilico Medicine (03696.HK) Inks AI Drug Discovery Deal Exceeding HK$931 Million Including Sales Milestones
NewTimeSpace Report: InSilico Medicine (03696.HK) announced that the company has entered into a strategic drug research and development partnership and signed relevant agreements with Qilu Pharmaceutical Group and its affiliate Shanghai Qilu Pharmaceutical Research Center.
Under the terms of the agreement, both parties will leverage InSilico Medicine's proprietary Pharma.AI solutions to collaboratively develop small molecule inhibitors targeting specific targets, focusing on the cardiovascular and metabolic disease areas. InSilico Medicine will utilize its self-developed Pharma.AI platform for the design and optimization of novel small molecule drugs for metabolic diseases, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization.
The total value of the agreement exceeds HK$931 million, comprising development and sales milestone payments, plus single-digit royalties on subsequent net sales.
According to the announcement, Qilu Pharmaceutical ranked third in the "China Pharmaceutical Industry Top 100" list in 2024, with over 320 products launched, including 79 domestic first-to-market or exclusive products exported to more than 100 countries and regions.
InSilico Medicine noted that the company is a global pioneer in biotechnology committed to integrating artificial intelligence and automation technologies to accelerate drug discovery. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
